Navigation Links
Statement by Ronald L. Stotish, Ph.D., President and CEO of AquaBounty Technologies
Date:6/16/2011

WALTHAM, Mass., June 16, 2011 /PRNewswire-USNewswire/ -- Background: The U.S. House of Representatives yesterday passed an amendment to H.R. 2112, the House agricultural appropriations bill, co-sponsored by Rep. Don Young (R-AK) and Rep. Lynn Woolsey (D-CA) to prohibit funding for U.S. Food and Drug Administration approval of salmon grown from AquaBounty Technologie's AquAdvantage salmon eggs.  The amendment was voted on by fewer than ten of the total 435 House members.

The U.S. FDA has conducted a rigorous 15-year review of thousands of pages of data and has concluded that these fish are exactly the same as any other Atlantic salmon and, therefore, are safe for consumption.  In addition, the fish will be sterile and required to be grown in self-contained inland tanks, so pose no threat to the environment.  Finally, the United Nations reports that the wild caught fisheries are severely stressed, with  major food species potentially extinct by 2050, yet the demand for fish protein is exploding worldwide. America currently imports more than 97% of the Atlantic salmon consumed here, so Young et al are really supporting foreign salmon producers.

Statement:

"This outrageous action is wrong on the facts, wrong on the process and wrong on the policy.  A handful of representatives have chosen to subvert the FDA's rigorous 15-year plus process. It completely ignores the results of a rigorous scientific review. This sort of political gamesmanship undermines the science-based system that protects the nation's health and safety. It is astonishing that Young and a few colleagues would try to game the system in this way."

"Whether or not you support this transgenic salmon, we should all agree these types of shenanigans have no place in a complex scientific debate.  These actions threaten the fundamental basis of a science-based regulatory process. Americans deserve better from their elected representatives."


'/>"/>
SOURCE AquaBounty Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Issues a Management Statement
2. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Sinovac Releases Statement on Healive Vaccine Suspension
5. CV Therapeutics Statement on Unsolicited Proposal From Astellas
6. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
7. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
8. Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
9. Advanced Life Sciences Announces Filing of Shelf Registration Statement
10. Amylin Issues Statement in Response to Carl Icahn
11. DuPont Statement on Obama Administration Biofuels Interagency Working Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , November 30, 2016 The global ... few players hold a dominant share in the overall ... Laboratories International, Inc., and Merck KGaA, held a lion,s ... Transparency Market Research observes that these companies are expected ... development products that are do not require rabbit pyrogen ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... Triangle Park, NC (PRWEB) , ... November 30, ... ... development company engaged in the development of a new orally administered treatment for ... testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):